Innovative Leadership at Palisade Bio with Sharon Skare
In a move that marks a significant development for Palisade Bio, the company has proudly announced the appointment of Sharon Skare, PhD(c), as Vice President and Global Head of Clinical Operations. With an impressive career that spans over 24 years in the pharmaceutical industry, Ms. Skare brings a wealth of expertise in clinical development, particularly in autoimmune, metabolic, gastrointestinal, and cardiovascular diseases.
Focus on Advancing Clinical Programs
Palisade Bio is dedicated to pushing forward the development of PALI-2108, its lead candidate aimed at treating ulcerative colitis and fibrostenotic Crohn’s disease. This commitment is evident in their plans for a Phase 2 Investigational New Drug (IND) submission, targeting the first half of 2026. The urgency in advancing these therapies highlights the significant unmet medical needs faced by millions of patients globally.
Sharon Skare's Extensive Expertise
Sharon Skare has had a remarkable career trajectory, with her previous role as Vice President and Global Head of Clinical Operations at Abivax. She has adeptly managed global clinical programs for pivotal therapies in ulcerative colitis and Crohn’s disease. Additionally, her experience at leading pharmaceutical companies like Pfizer and Arena Pharmaceuticals underscores her capability in navigating the complex clinical landscape. Ms. Skare's contribution to launching Etrasimod, which has become an important treatment in this arena, demonstrates her success and aligns perfectly with Palisade's mission.
Strategic Vision for PALI-2108
Palisade's innovative approach with PALI-2108 is a noteworthy focus for improving treatment modalities for inflammatory bowel disease (IBD). This product is designed as a prodrug to ensure that the active medication is released precisely where it's needed—within the lower intestine—promoting better therapeutic outcomes with fewer side effects. Such advancements are crucial for enhancing patient quality of life in treating chronic conditions like ulcerative colitis and Crohn’s disease.
A New Era for Clinical Operations
Dr. Mitchell Jones, the Chief Medical Officer of Palisade Bio, expressed enthusiasm about Ms. Skare's appointment, emphasizing her proven track record in global clinical operations. This strong leadership is expected to enhance the operational capabilities of Palisade Bio, streamlining processes as they prepare for this critical phase of development. The company is confident that her insights will play a pivotal role in achieving key clinical and regulatory goals.
Sharon Skare's Vision for Transformation
As Ms. Skare joins Palisade Bio, she seeks to spearhead initiatives aimed at transforming and redefining treatment options for patients. Her experience positions her well to address the challenges that come with developing new therapies, particularly those that combine efficacy and tolerability, which are essential for success in patients with IBD.
Advancing Patient-Centric Solutions
By leveraging her extensive operational experience, Ms. Skare plans to spearhead efforts to ensure that PALI-2108 meets the high standards required for therapeutic approval. Her leadership will be crucial as Palisade Bio aims to revolutionize treatment pathways, thereby improving health outcomes for individuals battling these significant health challenges. The commitment to patient-centric solutions reflects the company’s core belief in transforming lives through innovative therapeutics.
Conclusion: Looking Ahead at Palisade Bio
With the recent advancements in clinical development, Palisade Bio is well-positioned for future successes. Under Sharon Skare's leadership, the company is expected to not only meet its imminent clinical milestones but also set new benchmarks for innovation in the industry. This strategic direction is not just about developing new treatments; it's about enhancing the lives of patients who face the complex realities of autoimmune disease therapies.
Frequently Asked Questions
What led to the appointment of Sharon Skare at Palisade Bio?
Sharon Skare was appointed due to her extensive experience in global clinical operations, which is vital for advancing the company’s clinical programs.
What is PALI-2108 and its significance?
PALI-2108 is an innovative therapy designed to treat ulcerative colitis and fibrostenotic Crohn’s disease, emphasizing targeted delivery to improve patient outcomes.
When is the IND submission for PALI-2108 planned?
The IND submission for PALI-2108 is planned for the first half of 2026, as part of the company's advancement into Phase 2 studies.
What can we expect from Palisade Bio in the near future?
With the new leadership and focused development programs, Palisade Bio aims to achieve significant clinical milestones that will enhance treatment options in the therapeutic landscape.
How does the company plan to address patient needs?
Palisade Bio is committed to developing therapies that not only demonstrate efficacy but also prioritize patient tolerability, enhancing the overall treatment experience.
